Mizuho Securities analyst Difei Yang reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) today and set a

Mizuho Securities analyst Difei Yang reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) today and set a
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO – Research Report),
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO – Research Report),
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Selecta Biosciences (SELB
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO – Research Report),
Bluebird Bio (BLUE – Research Report) received a Hold rating and a $34.00 price target from Mizuho Securities analyst Difei